• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

European Commission approves adalimumab for paediatric uveitis


The European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.

The European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.

Used for years in rheumatoid arthritis and other autoimmune disorders, the drug gained European approval in May 2016 for use in noninfectious intermediate and posterior uveitis and panuveitis in adult patients who cannot be treated effectively with corticosteroids. It received similar approval in adults in June 2016 from the U.S. Food and Drug Administration (FDA).

Adalimumab is a fully human anti-tumour necrosis factor-alpha (TNF-alpha) monoclonal antibody. Some research has suggested that the proinflammatory cytokine TNF-alpha plays a role in uveitic inflammation. Its levels in serum and aqueous humour are up-regulated in patients with uveitis.


Randomised trial

The commission based its decision on SYCAMORE2, a double-masked, randomised, placebo-controlled clinical trial. The results showed that adalimumab combined with methotrexate significantly delayed the time to treatment failure compared with methotrexate plus placebo in children 2 years of age and older with active juvenile idiopathic arthritis-associated uveitis.

"These results demonstrate adalimumab has the potential to help many children who have failed standard treatments," said Dr Athimalaipet Ramanan, paediatric rheumatologist at University Hospitals Bristol NHS Trust and principal investigator of the SYCAMORE study, in a press release.

SYCAMORE2 was sponsored by the University Hospitals Bristol NHS Foundation Trust and coordinated by the Clinical Trials Research Centre at the University of Liverpool.

Investigators assigned patients who were taking a stable dose of methotrexate in a 2:1 ratio to receive either adalimumab (at a dose of 20 mg or 40 mg, according to body weight) or placebo, administered subcutaneously every two weeks.

Patients continued the trial regimen until treatment failure or until 18 months had elapsed. The researchers followed them for up to 2 years, including 6 months off the study drug.

The primary endpoint was the time to treatment failure, defined as meeting at least one of the following criteria: multiple components of intraocular inflammation, worsening or development of ocular comorbidities, use of concomitant medications that were not allowed or that did not follow pre-specified criteria, and suspension of treatment for an extended period of time.

The Independent Data Safety and Monitoring Committee (IDSMC) recommended unmasking the trial early after seeing that adalimumab combined with methotrexate controlled ocular inflammation better and was associated with a lower rate of treatment failure in 90 patients than the combination of methotrexate and placebo.

The pre-specified stopping criteria were met after the enrolment of 90 of 114 patients. Researchers observed 16 treatment failures in 60 patients (27%) in the adalimumab group versus 18 treatment failures in 30 patients (60%) in the placebo group (hazard ratio, 0.25; 95% confidence interval [CI], 0.12 to 0.49; (P<0.0001). This was the pre-specified stopping boundary.

Patients taking adalimumab experienced 10.7 (95% CI 9.26 to 10.89) adverse events per patient-year, compared with 6.51 (95% CI, 5.26 to 7.77) for patients taking the placebo.

A higher proportion of these adverse events were serious in the patients taking adalimumab. These patients suffered 0.29 events per patient-year (95% CI 0.15 to 0.43) versus 0.19 events per patient-year for the patients taking placebo (95% CI 0.00 to 0.40).



Uveitis is an inflammation of the uvea, which includes the iris, choroid and the ciliary body in the eye. If left untreated, it can lead to vision loss, including cataracts, glaucoma and cystoid macular oedema.

By some estimates, severe vision loss occurs in 25% to 30% of paediatric uveitis cases, making early diagnosis and treatment essential to preserve vision in children with the disease. Juvenile idiopathic arthritis is the most common systemic disorder associated with uveitis in children, accounting for more than 75% of cases of paediatric anterior uveitis.

Clinicians have long relied on corticosteroids to treat uveitis. These treatments frequently cause ocular and systemic adverse events, so immunosuppressant therapies, including methotrexate, have emerged as an alternative, or second-line therapy.

Adalimumab effectively lowers inflammation in multiple disorders.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.